Sequence: RQIKIWFQNRRMKWKK (with C-terminal Cys in construct: ...KKC)
| Experiment Id | EXP001773 |
|---|---|
| Paper | Lung Delivery Studies Using siRNA Conjugated to TAT(48-60) and Penetratin Reveal Peptide Induced Red |
| Peptide | Penetratin |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | low |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | 10 nmol dose as peptide–siRNA conjugate (in 20 µL; ~500 µM) |
| Rna Concentration | 10 nmol siRNA dose (conjugated; 20 µL) |
| Mixing Ratio | covalent conjugate (N/A) |
| Formulation Format | disulfide-linked peptide–siRNA conjugate |
| Formulation Components | CPP (TAT(48-60) or penetratin) conjugated to siRNA sense strand; duplex siRNA |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | BALB/c mice (male, 20–25 g); lung (intratracheal) |
| Administration Route | Intratracheal (20 µL PBS) |
| Output Type | p38 MAPK mRNA knockdown in whole lung (RT-qPCR) |
| Output Value | ~47% knockdown at 6 h (reported), but penetratin alone ~30% knockdown |
| Output Units | |
| Output Notes | Strong confounding by penetratin peptide alone; penetratin-siRNA also triggered innate immune markers. |
| Toxicity Notes | Penetratin-siRNA increased TNF-α, IL-12p40, and IFN-α in lung (innate immune activation). |
| Curation Notes |